Filed: 8/14/2026ACC: 0001104659-26-097121
📋 What this filing means
FORESITE CAPITAL MANAGEMENT V, LLC filed this quarterly 13F‑HR report disclosing 9 equity positions with a total reported market value of $362.20M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
9
Positions
$362.20M
Total AUM (reported)
11.53M
Total Shares
Allocation by class
COM$336.61M92.9%
COM CL A$25.59M7.1%
Portfolio Concentration
Top 3$269.97M74.5%
4–10$92.23M25.5%
Top 3 weight
74.5%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 11.53M
Sole
Full voting authority
11.53M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole9
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings9
Rows:
ALUMIS INC.
SOLEShares5.90M
TypeSH
Market value$165.94M
45.81%
Sole
5.90M
Shared
0.00
None
0.00
CG Oncology, Inc.
SOLEShares1.08M
TypeSH
Market value$76.67M
21.17%
Sole
1.08M
Shared
0.00
None
0.00
Disc Medicine, Inc.
SOLEShares374.07K
TypeSH
Market value$27.36M
7.55%
Sole
374.07K
Shared
0.00
None
0.00
Hims & Hers Health, Inc.
SOLEShares738.15K
TypeSH
Market value$25.59M
7.07%
Sole
738.15K
Shared
0.00
None
0.00
Pharvaris N.V.
SOLEShares664.14K
TypeSH
Market value$22.97M
6.34%
Sole
664.14K
Shared
0.00
None
0.00
Eikon Therapeutics, Inc.
SOLEShares1.32M
TypeSH
Market value$17.21M
4.75%
Sole
1.32M
Shared
0.00
None
0.00
Odyssey Therapeutics, Inc.
SOLEShares713.11K
TypeSH
Market value$13.34M
3.68%
Sole
713.11K
Shared
0.00
None
0.00
Lyell Immunopharma, Inc.
SOLEShares476.39K
TypeSH
Market value$6.69M
1.85%
Sole
476.39K
Shared
0.00
None
0.00
Nurix Therapeutics, Inc.
SOLEShares265K
TypeSH
Market value$6.43M
1.77%
Sole
265K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
ALUMIS INC.SOLE | COM | 5.90M | SH | $165.94M 45.81% | 5.90M | 0.00 | 0.00 |
CG Oncology, Inc.SOLE | COM | 1.08M | SH | $76.67M 21.17% | 1.08M | 0.00 | 0.00 |
Disc Medicine, Inc.SOLE | COM | 374.07K | SH | $27.36M 7.55% | 374.07K | 0.00 | 0.00 |
Hims & Hers Health, Inc.SOLE | COM CL A | 738.15K | SH | $25.59M 7.07% | 738.15K | 0.00 | 0.00 |
Pharvaris N.V.SOLE | COM | 664.14K | SH | $22.97M 6.34% | 664.14K | 0.00 | 0.00 |
Eikon Therapeutics, Inc.SOLE | COM | 1.32M | SH | $17.21M 4.75% | 1.32M | 0.00 | 0.00 |
Odyssey Therapeutics, Inc.SOLE | COM | 713.11K | SH | $13.34M 3.68% | 713.11K | 0.00 | 0.00 |
Lyell Immunopharma, Inc.SOLE | COM | 476.39K | SH | $6.69M 1.85% | 476.39K | 0.00 | 0.00 |
Nurix Therapeutics, Inc.SOLE | COM | 265K | SH | $6.43M 1.77% | 265K | 0.00 | 0.00 |